Medicine by Sfakianakis Alexandros

Genomic and transcriptomic comparison of post-radiation versus sporadic sarcomas

• Tom Lesluyes, 
• Jessica Baud, 
• Gaëlle Pérot, 
• Céline Charon-Barra, 
• Axel You, 
• Isabelle Valo, 
• Céline Bazille, 
• Florence Mishellany, 
• Agnès Leroux, 
• Sophie Renard-Oldrini, 
• Philippe Terrier, 
• Axel Le Cesne, 
• Marick Laé, 
• Sophie Piperno-Neumann, 
• Sylvie Bonvalot, 
• Agnès Neuville, 
• Françoise Collin, 
• Philippe Maingon, 
• Jean-Michel Coindre & 
• Frédéric Chibon 

Modern Pathology (2019) | Download Citation

Abstract

Post-radiation sarcomas are rare secondary cancers arising from radiation therapies. To date, few genetic specificities have been described for such malignancies and the oncogenesis of sarcomas with complex genetics (both sporadic and post-radiation) remains largely misunderstood. We performed genomic and transcriptomic analyses on 77 post-radiation sarcomas using DNA-array and RNA sequencing. Consequently, we were able to investigate changes in copy number variations, transcriptome profiling, fusion gene expression, and mutational landscapes. We compare these data to a reference cohort of 93 sporadic sarcomas. At genomic level, similar chromosomal complexity was observed both in post-radiation and sporadic sarcomas with complex genetics. We found more frequent CDKN2A and CDKN2B(coding for p14/p16 and p15 proteins, respectively; at 9p21.3) losses in post-radiation (71%) than in sporadic tumors (39%; P = 6.92e−3). Among all detected fusion genes and punctual variations, few specificities were observed between these groups and such alterations are not able to drive a strong and specific oncogenesis. Recurrent MYC amplifications (96%) and KDR variants (8%) were detected in post-radiation angiosarcomas, in agreement with the literature. Transcriptomic analysis of such angiosarcomas revealed two distinct groups harboring different genomic imbalances (in particular gains of 17q24.2-17qter) with different clinical courses according to patient’s vital status. Differential gene expression analysis permitted to focus on the immune response as a potential actor to tumor aggressiveness. Histochemistry validated a lower inflammation and lower immune infiltrate at tumor periphery for highly aggressive angiosarcomas. Our results provide new genomic and transcriptomic information about post-radiation sarcomas. The techniques we used (RNA-seq and DNA-arrays) did not highlight major differences in sarcomas with complex genetics depending on the radiation context, revealing similar patterns of transcriptomic profiles and chromosomal copy number variations. Additional characterizations, particularly whole genome sequencing, could measure changes in DNA following radiation therapy in such malignancies and may precise their oncogenesis.